Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization
Version of Record online: 6 FEB 2013
© 2013 Blackwell Publishing Ltd
British Journal of Haematology
Volume 161, Issue 1, pages 104–116, April 2013
How to Cite
Udi, J., Schüler, J., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J., Schnerch, D., Follo, M., Wäsch, R. and Engelhardt, M. (2013), Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. British Journal of Haematology, 161: 104–116. doi: 10.1111/bjh.12226
- Issue online: 15 MAR 2013
- Version of Record online: 6 FEB 2013
- Manuscript Accepted: 20 DEC 2012
- Manuscript Received: 16 OCT 2012
Fig S1. Combined effect of EGCG and bortezomib on cell death in L363 cells.
Fig S2. Body weight changes of non-tumor bearing NSG mice under treatment with Bortezomib in different doses and schedules.
Fig S3. Body weight changes of non-tumor bearing NSG mice under treatment with Sorafenib in different doses and schedules.
Fig S4. Chemosensitivity of L363 cells in i.t. injected mice treated with control vehicle, bortezomib and sorafenib determined by flow cytometry.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.